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Screening for HIV Infection
US Preventive Services Task Force
Recommendation Statement
US Preventive Services Task Force
IMPORTANCE Approximately 1.1 million persons in the United States are currently living with
HIV, andmore than 700000 persons have died of AIDS since the first cases were reported in
1981. There were approximately 38 300 new diagnoses of HIV infection in 2017. The
estimated prevalence of HIV infection among persons 13 years and older in the United States
is 0.4%, and data from the Centers for Disease Control and Prevention show a significant
increase in HIV diagnoses starting at age 15 years. An estimated 8700women living with HIV
give birth each year in the United States. HIV can be transmitted frommother to child during
pregnancy, labor, delivery, and breastfeeding. The incidence of perinatal HIV infection in the
United States peaked in 1992 and has declined significantly following the implementation of
routine prenatal HIV screening and the use of effective therapies and precautions to prevent
mother-to-child transmission.
OBJECTIVE To update the 2013 US Preventive Services Task Force (USPSTF) recommendation
on screening for HIV infection in adolescents, adults, and pregnant women.
EVIDENCE REVIEW The USPSTF reviewed the evidence on the benefits and harms of
screening for HIV infection in nonpregnant adolescents and adults, the yield of screening for
HIV infection at different intervals, the effects of initiating antiretroviral therapy (ART)
at a higher vs lower CD4 cell count, and the longer-term harms associated with currently
recommended ART regimens. The USPSTF also reviewed the evidence on the benefits
(specifically, reduced risk of mother-to-child transmission of HIV infection) and harms of
screening for HIV infection in pregnant persons, the yield of repeat screening for HIV at
different intervals during pregnancy, the effectiveness of currently recommended ART
regimens for reducingmother-to-child transmission of HIV infection, and the harms of ART
during pregnancy to themother and infant.
FINDINGS The USPSTF found convincing evidence that currently recommended HIV tests
are highly accurate in diagnosing HIV infection. The USPSTF found convincing evidence
that identification and early treatment of HIV infection is of substantial benefit in reducing
the risk of AIDS-related events or death. The USPSTF found convincing evidence that
the use of ART is of substantial benefit in decreasing the risk of HIV transmission to
uninfected sex partners. The USPSTF also found convincing evidence that identification and
treatment of pregnant women living with HIV infection is of substantial benefit in reducing
the rate of mother-to-child transmission. The USPSTF found adequate evidence that ART is
associated with some harms, including neuropsychiatric, renal, and hepatic harms, and an
increased risk of preterm birth in pregnant women. The USPSTF concludes with high
certainty that the net benefit of screening for HIV infection in adolescents, adults,
and pregnant women is substantial.
CONCLUSIONS AND RECOMMENDATION The USPSTF recommends screening for HIV infection
in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are
at increased risk of infection should also be screened. (A recommendation) The USPSTF
recommends screening for HIV infection in all pregnant persons, including those who present
in labor or at delivery whose HIV status is unknown. (A recommendation)
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T heUSPreventiveServicesTaskForce (USPSTF)makes rec-ommendations about theeffectivenessof specific preven-tivecare services forpatientswithoutobvious relatedsigns
or symptoms.
It bases its recommendations on the evidence of both the
benefits and harms of the service and an assessment of the bal-
ance. The USPSTF does not consider the costs of providing a ser-
vice in this assessment.
TheUSPSTFrecognizes that clinicaldecisions involvemorecon-
siderations than evidence alone. Clinicians should understand the
evidence but individualize decision making to the specific patient
or situation. Similarly, the USPSTF notes that policy and coverage
decisions involve considerations in addition to theevidenceof clini-
cal benefits and harms.
Summary of Recommendations and Evidence
TheUSPSTF recommends that clinicians screen forHIV infection in
adolescentsandadultsaged15 to65years.Youngeradolescentsand
older adults who are at increased risk of infection should also be
screened (A recommendation) (Figure 1).
The USPSTF recommends that clinicians screen for HIV infec-
tion in all pregnant persons, including those who present in labor
or at delivery whose HIV status is unknown. (A recommendation)
See the Clinical Considerations section for more information
about assessment of risk, screening intervals, and rescreening
in pregnancy.
Rationale
Importance
Approximately 1.1 million persons in the United States are cur-
rently living with HIV,1 andmore than 700000 persons have died
of AIDS since the first cases were reported in 1981.2 The esti-
mated prevalence of HIV infection among persons 13 years and
older in the United States is 0.4% (0.7% in males and 0.2% in
females),3 and data from the Centers for Disease Control and Pre-
vention (CDC) 2017 HIV Surveillance Report show a significant
increase in HIV diagnoses starting at age 15 years (compared with
ages 13-14 years).2 The annual number of new cases of HIV infec-
tion diagnosed in the United States has decreased slightly in
recent years, from about 41 200 new cases in 2012 to 38 300 in
2017.2 Approximately 15% of persons living with HIV are unaware
of their infection.1,3,4 It is estimated that persons unaware of their
HIV status are responsible for 40% of transmission of HIV in the
United States.4
An estimated 8700 women living with HIV give birth
each year in the United States.5 HIV can be transmitted from
mother to child during pregnancy, labor, delivery, and breastfeed-
ing. The incidence of perinatal HIV infection in the United States
peaked in 19926 and has declined significantly following the
implementation of routine prenatal HIV screening and the use of
effective therapies and precautions to prevent mother-to-child
transmission. Nearly 22 000 perinatal infections were prevented
between 1994 and 2010 because of screening and preven-
tive measures.7
Detection
The USPSTF found convincing evidence that currently recom-
mended HIV tests are highly accurate in diagnosing HIV infection.
Benefits of Detection and Early Treatment
The USPSTF found convincing evidence that identification and
early treatment of HIV infection is of substantial benefit in reduc-
ing the risk of AIDS-related events or death. The USPSTF found
convincing evidence that the use of antiretroviral therapy (ART) is
of substantial benefit in decreasing the risk of HIV transmission to
uninfected sex partners. The USPSTF also found convincing evi-
dence that identification and treatment of pregnant women living
with HIV infection is of substantial benefit in reducing the rate of
mother-to-child transmission. The overall magnitude of the ben-
efit of screening for HIV infection in adolescents, adults, and
pregnant women is substantial.
Harms of Detection and Early Treatment
The USPSTF found adequate evidence that individual antiretrovi-
ral drugs, ART drug classes, and ART combinations are associated
with some harms, including neuropsychiatric, renal, and hepatic
harms and an increased risk of preterm birth in pregnant women.
The overallmagnitude of the harms of screening for and treatment
of screen-detected HIV infection in adolescents, adults, and preg-
nant women is small.
USPSTF Assessment
The USPSTF concludes with high certainty that the net benefit of
screening for HIV infection in adolescents, adults, and pregnant
women is substantial.
Clinical Considerations
Patient Population Under Consideration
This recommendation applies to adolescents, adults, and all preg-
nant persons regardless of age (Figure 2). Based on the age-
stratified incidence of HIV infection and data on sexual activity in
youth, theUSPSTF recommends screening forHIV infectionbegin-
ning at age 15 years. Adolescents younger than 15 years and adults
older than 65 years should be screened if they have risk factors for
HIV infection.
Assessment of Risk
Although all adolescents and adults aged 15 to 65 years should be
screened, thereareanumberof risk factors that increaserisk.Among
adolescents younger than 15 years and adults older than 65 years,
clinicians should consider the risk factors of their patients, espe-
cially those with new sex partners, and offer testing to patients at
increased risk.
Most (67%) new diagnoses of HIV infection are attributed to
male-to-male sexual contact,2 and the estimated prevalence of HIV
infection among men who have sex with men is 12%.3 Injection
drug use is another important risk factor for HIV infection; the esti-
mated prevalence of HIV infection among personswho inject drugs
is 1.9%.3 In 2017, male individuals 13 years and older accounted for
81% of new diagnoses of HIV infection.2 Most (83%) of these new
diagnoses of HIV infection were attributed to male-to-male sexual
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contact, while 9% were attributed to heterosexual contact, 4% to
injection drug use, and 4% to both male-to-male sexual contact
and injection drug use.2 Among female individuals 13 years and
older, 87% of all new diagnoses were attributed to heterosexual
contact and 12% to injection drug use.2
Additional risk factors for HIV infection include having anal
intercourse without a condom, having vaginal intercourse with-
out a condom and with more than 1 partner whose HIV status is
unknown, exchanging sex for drugs or money (transactional sex),
having other sexually transmitted infections (STIs) or a sex part-
ner with an STI, and having a sex partner who is living with HIV or
is in a high-risk category. Persons who request testing for STIs,
including HIV, are also considered at increased risk.
TheUSPSTF recognizes that these risk categories are notmutu-
ally exclusive, that the degree of risk exists on a continuum, and that
personsmaynotbeawareof theHIVor riskstatusof their sexpartner
orthepersonwithwhomtheyshareinjectiondrugequipment.Patients
may also be reluctant to disclose risk factors to clinicians.
Screening Tests
Current CDC guidelines recommend testing for HIV infection
with an antigen/antibody immunoassay approved by the US Food
Figure 1. USPSTF Grades and Levels of Evidence
What the USPSTF Grades Mean and Suggestions for Practice
Grade Definition
A The USPSTF recommends the service. There is high certainty that the net benefit is substantial. Offer or provide this service.
Suggestions for Practice
B The USPSTF recommends the service. There is high certainty that the net benefit is moderate, or
there is moderate certainty that the net benefit is moderate to substantial.
Offer or provide this service.
C
The USPSTF recommends selectively offering or providing this service to individual patients
based on professional judgment and patient preferences. There is at least moderate certainty
that the net benefit is small.
Offer or provide this service for selected
patients depending on individual
circumstances.
D The USPSTF recommends against the service. There is moderate or high certainty that the service
has no net benefit or that the harms outweigh the benefits.
Discourage the use of this service.
I statement
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits
and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of
benefits and harms cannot be determined.
Read the Clinical Considerations section
of the USPSTF Recommendation
Statement. If the service is offered,
patients should understand the
uncertainty about the balance of benefits
and harms.
USPSTF Levels of Certainty Regarding Net Benefit
Level of Certainty Description
High
The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care
populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be
strongly affected by the results of future studies.
Moderate
The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate
is constrained by such factors as 
the number, size, or quality of individual studies.
inconsistency of findings across individual studies.
limited generalizability of findings to routine primary care practice.
lack of coherence in the chain of evidence.
As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large
enough to alter the conclusion.
The USPSTF defines certainty as “likelihood that the USPSTF assessment of the net benefit of a preventive service is correct.” The net benefit is defined as
benefit minus harm of the preventive service as implemented in a general, primary care population. The USPSTF assigns a certainty level based on the nature
of the overall evidence available to assess the net benefit of a preventive service.
Low
The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of
the limited number or size of studies.
important flaws in study design or methods.
inconsistency of findings across individual studies.
gaps in the chain of evidence.
findings not generalizable to routine primary care practice.
lack of information on important health outcomes.
More information may allow estimation of effects on health outcomes.
USPSTF indicates US Preventive Services Task Force.
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and Drug Administration that detects HIV-1 and HIV-2 antibodies
and the HIV-1 p24 antigen, with supplemental testing after a reac-
tive assay to differentiate between HIV-1 and HIV-2 antibodies.8,9
If supplemental testing for HIV-1/HIV-2 antibodies is nonreactive
or indeterminate (or if acute HIV infection or recent exposure
is suspected or reported), an HIV-1 nucleic acid test is recom-
mended to differentiate acute HIV-1 infection from a false-
positive test result.8,9
Antigen/antibody tests for HIV are highly accurate, with re-
portedsensitivity rangingfrom99.76%to100%andspecificity rang-
ing from99.50% to 100%, and results can be available in 2 days or
less.8 Rapid antigen/antibody tests are also available.9
WhenusingarapidHIVtest forscreening,positive results should
be confirmed. Pregnant women presenting in labor with unknown
HIV status shouldbe screenedwith a rapidHIV test to get results as
soon as possible.
Screening Intervals
The USPSTF found insufficient evidence to determine appropri-
ate or optimal time intervals or strategies for repeat HIV screen-
ing. Repeat screening is reasonable for persons known to be
at increased risk of HIV infection, such as sexually active men
who have sex with men; persons with a sex partner who is living
with HIV; or persons who engage in behaviors that may convey an
increased risk of HIV infection, such as injection drug use, transac-
tional sex or commercial sex work, having 1 or more new (ie, since
a prior HIV test) sex partners whose HIV status is unknown,
or having other factors that can place a person at increased risk
Figure 2. Clinical Summary: Screening for HIV Infection
Population
Recommendation 
Adolescents and adults aged 15 to 65 years
Screen for HIV infection.
Grade: A
Pregnant persons
Screen for HIV infection.
Grade: A
Risk Assessment
Screening Intervals
For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please
go to https://www.uspreventiveservicestaskforce.org.   
Although all adolescents and adults aged 15 to 65 years should be screened, there are a number of risk factors that increase risk.
Among adolescents younger than 15 years and adults older than 65 years, clinicians should offer testing to patients at increased
risk. Most new diagnoses of HIV infection are attributed to male-to-male sexual contact; injection drug use is another important
risk factor. Additional risk factors include having anal intercourse without a condom, having vaginal intercourse without a condom
and with more than 1 partner whose HIV status is unknown, exchanging sex for drugs or money (transactional sex), having other
STIs or a sex partner with an STI, and having a sex partner who is living with HIV or is in a high-risk category. Persons who request
testing for STIs, including HIV, are also considered to be at increased risk.
The USPSTF found insufficient evidence to determine appropriate or optimal time intervals or strategies for repeat HIV screening.
However, repeat screening is reasonable for persons known to be at increased risk of HIV infection, such as sexually active men
who have sex with men; persons with a sex partner who is living with HIV; or persons who engage in behaviors that may convey
an increased risk of HIV infection, such as injection drug use, transactional sex or commercial sex work, having 1 or more new
sex partners whose HIV status is unknown, or having other factors that can place a person at increased risk of HIV infection
(see “Risk Assessment”). Repeat screening is also reasonable for persons who live or receive medical care in a high-prevalence
setting, such as a sexually transmitted disease clinic, tuberculosis clinic, correctional facility, or homeless shelter.
The CDC and ACOG recommend repeat prenatal screening for HIV during the third trimester of pregnancy in women with risk
factors for HIV acquisition and in women living or receiving care in high-incidence settings, and the CDC notes that repeat
screening for HIV during the third trimester may be considered in all women. 
Screening Tests
Current CDC guidelines recommend testing for HIV infection with an antigen/antibody immunoassay approved by the US Food
and Drug Administration that detects HIV-1 and HIV-2 antibodies and the HIV-1 p24 antigen, with supplemental testing following
a reactive assay to differentiate between HIV-1 and HIV-2 antibodies. If supplemental testing for HIV-1/HIV-2 antibodies is
nonreactive or indeterminate (or if acute HIV infection or recent exposure is suspected or reported), an HIV-1 nucleic acid test
is recommended to differentiate acute HIV-1 infection from a false-positive test result.
Treatment and
Interventions
No cure or vaccine for HIV infection currently exists. However, early initiation of ART and other interventions effectively reduce
the risk of clinical progression to AIDS, AIDS-defining clinical events, and mortality. Also, studies to date have shown that when
ART leads to viral suppression, no cases of virologically linked HIV transmission have been observed. Interventions other than
ART include prophylaxis for opportunistic infections when clinically indicated, immunizations, and cancer screening. In addition,
ART treatment in pregnant persons living with HIV and use of other precautions substantially decrease the risk of transmission
to the fetus, newborn, or infant.
ACOG indicates American College of Obstetricians and Gynecologists; ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; STI, sexually
transmitted infection; USPSTF, US Preventive Services Task Force.
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of HIV infection (see the Assessment of Risk section). Repeat
screening is also reasonable for persons who live or receive medi-
cal care in a high-prevalence setting, such as a sexually transmit-
ted disease clinic, tuberculosis clinic, correctional facility, or
homeless shelter. The CDC recommends annual screening in per-
sons at increased risk10 but recognizes that clinicians may wish to
screen high-risk men who have sex with men more frequently
(eg, every 3 or 6 months) depending on the patient’s risk factors,
local HIV prevalence, and local policies.11 Routine rescreening may
not be necessary for persons who have not been at increased risk
since they last tested negative for HIV.
The USPSTF found no evidence on the yield of repeat prena-
tal screening for HIV compared with 1-time screening during a
single pregnancy. The CDC10 and the American College of Obste-
tricians and Gynecologists (ACOG)12 recommend repeat prenatal
screening for HIV during the third trimester of pregnancy in
women with risk factors for HIV acquisition and in women living
or receiving care in high-incidence settings, and the CDC notes
that repeat screening for HIV during the third trimester in all
women who test negative early in pregnancy may be considered.
Women screened during a previous pregnancy should be
rescreened in subsequent pregnancies.
Treatment
No cure or vaccine for HIV infection currently exists. However,
early initiation of ART and other interventions effectively reduce
the risk of clinical progression to AIDS, AIDS-defining clinical
events, and mortality. Also, studies to date have shown that when
ART leads to viral suppression, no cases of virologically linked HIV
transmission have been observed. Interventions other than ART
include prophylaxis for opportunistic infections when clinically
indicated, immunizations, and cancer screening. In addition, ART
treatment in pregnant women living with HIV and use of other
precautions substantially decrease the risk of transmission to the
fetus, newborn, or infant.
The clinical treatment of HIV infection is a dynamic scientific
field. The Panel on Antiretroviral Guidelines for Adults and Ado-
lescents of the US Department of Health and Human Services
regularly updates guidelines for HIV treatment regimens.13
Additional Approaches to Prevention
The USPSTF recognizes that the most effective strategy for
reducing HIV-related morbidity and mortality in the United States
is primary prevention, or avoidance of exposure to HIV infection.
Avoiding behaviors that may convey an increased risk of HIV
infection and consistent use of condoms can decrease the risk of
transmission of HIV and other STIs. The USPSTF recommends
providing intensive behavioral counseling for all sexually active
adolescents and for adults at increased risk of STIs.14
The Community Preventive Services Task Force has made
several recommendations related to the prevention of HIV/AIDS
and other STIs.15
Prophylactic intervention with antiretroviral medications,
both preexposure and postexposure, can prevent HIV infection.
Postexposure prophylaxis is used in persons who do not have HIV
and may have been exposed to it via sexual contact, occupational
or nonoccupational needle stick or other injury, or sharing injec-
tion drug equipment. When initiated soon after possible expo-
sure, postexposure prophylaxis can prevent HIV infection. Preex-
posure prophylaxis is used in persons who do not have HIV and
are at high risk of acquiring HIV infection. It consists of antiretro-
viral medication taken every day, before potential exposure. The
USPSTF recommends offering preexposure prophylaxis to per-
sons at high risk of HIV acquisition.16
Useful Resources
More information about HIV and AIDS is available at HIV.gov17 and
from the CDC.18 The CDC has made recommendations on screen-
ing for HIV in adolescents, adults, and pregnant women in health
care settings10 and the prevention of HIV transmission in adoles-
cents and adults living with HIV19; guidelines on the use of ART
and the potential adverse effects of ART are regularly updated at
https://www.aidsinfo.nih.gov.13
Other Considerations
Implementation
As recommended by the CDC, HIV screening should be voluntary
and performed only with the patient’s knowledge and
understanding.10 Patients should be informed orally or in writing
that HIV testing will be performed unless they decline (known as
“opt-out screening”). Patients should receive an explanation of
HIV infection and the meaning of positive and negative test
results. Patients should also be offered the opportunity to ask
questions and to decline testing.
The substantial benefit of screening is realized only if detec-
tion of HIV is followed by initiation of appropriate ART and provi-
sion of other services for persons found to have HIV. Thus, entry
into care for persons identified as having HIV is essential. The CDC
provides guidance on counseling, referral to care, treatment, and
prevention of HIV transmission.19,20 Clinicians should be aware
that some persons with HIV may face substantial barriers to
receiving appropriate services.
Research Needs and Gaps
Research isneededon theyieldof repeatvs 1-timescreening forHIV
and different repeat screening intervals to inform recommenda-
tions on optimal screening intervals. Data on optimal rescreening
strategies in pregnant women are needed.
Persons who initiate ART tend to continue receiving it for an
extended length of time. Thus, continued research on the poten-
tial harms of long-term use of ART is an important research need.
Further research is also needed to understand the effects of in
utero exposure to ART on pregnancy outcomes and long-term
effects in exposed children, to optimize the selection of ART regi-
mens during pregnancy.
Discussion
Burden of Disease
Since the first cases of AIDS were reported in 1981, more than
700000 persons in the United States have died of AIDS.2 The
CDC estimates that 1.1 million persons in the United States are cur-
rently living with HIV infection, including an estimated 15% who
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are unaware of their infection.1,3,4 The annual number of new HIV
diagnoses in the United States has decreased slightly in recent
years, from about 41 200 new diagnoses in 2012 to 38 300 in
2017.2 Of new diagnoses of HIV infection in 2017, 81% were
among males and 19% were among females.2 Groups dispropor-
tionately affected by HIV infection in the United States include
men who have sex with men, black/African American popula-
tions, and Hispanic/Latino populations. For example, the esti-
mated overall prevalence of HIV infection in the United States
is 0.4%, while the estimated prevalence among men who have
sex with men is 12%.3 From 2012 to 2017, HIV diagnosis rates
increased in adults aged 25 to 29 years, as well as in the American
Indian/Alaska Native population.2
Perinatal HIV transmission has decreased substantially
since its peak in 1992.6 There were 99 diagnoses of perinatally
acquired HIV infection in 2016,2 and approximately 8700 women
living with HIV give birth each year.5 There are racial/ethnic dis-
parities in rates of perinatally acquired HIV infection; rates are
5 times greater in black/African American women than in white
or Hispanic/Latino women.21 Of the 99 diagnoses of perinatally
acquired HIV infection reported in 2016, 65% occurred in black/
African American mothers.21
Scope of Review
To update its 2013 recommendation, the USPSTF commissioned a
systematic evidence review22,23 on the benefits and harms of
screening for HIV infection in nonpregnant adolescents and
adults, the yield of screening for HIV infection at different inter-
vals, the effects of initiating ART at a higher (ie, >500 cells/mL3)
vs lower CD4 (a type of white blood cell in the immune system)
count, and the longer-term harms associated with currently rec-
ommended ART regimens. The USPSTF also commissioned a sys-
tematic evidence review24,25 on the benefits (specifically,
reduced risk of mother-to-child transmission of HIV infection) and
harms of screening for HIV infection in pregnant persons, the
yield of repeat screening for HIV at different intervals during preg-
nancy, the effectiveness of currently recommended ART regi-
mens for reducing mother-to-child transmission of HIV infection,
and the harms of ART during pregnancy to the mother and infant.
Accuracy of Screening Tests
Currently recommended antigen/antibody tests for HIV are highly
accurate, with reported sensitivity ranging from 99.76% to 100%
and specificity ranging from 99.50% to 100%.8 Recommended
rapid HIV tests have similar sensitivity and somewhat lower
reported specificity ranging from 98.6% to 100%.26
Effectiveness of Early Detection and Treatment
The USPSTF found no randomized clinical trials (RCTs) or observa-
tional studies that compared clinical outcomes between adoles-
cents and adults screened and not screened for HIV infection. The
USPSTFfoundnostudies thatevaluatedtheyieldof repeatedscreen-
ing for HIV compared with 1-time screening or that compared the
yield of different strategies for repeat screening (eg, risk-based
screening vs routine repeat testing or repeat screening at different
intervals) inadolescentsandadults. TheUSPSTFalso foundnostud-
ies comparing the yield of 1-time vs repeat screening or of different
frequencies of screening for HIV infection in pregnancy.
The USPSTF reviewed 3 RCTs—the HIV Prevention Trials Net-
work (HPTN 052) trial (n = 1763),27,28 the International Network
for Strategic Initiatives in Global HIV Trials Strategic Timing
of Antiretroviral Treatment (INSIGHT START or START) trial
(n = 4685),29 and the Early Antiretroviral Treatment and/or Early
Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults
(TEMPRANO ANRS) trial (n = 2056)30—and 3 large fair-quality
cohort studies, ranging in sample size from 3532 to 55 826 (total
n = 63 478),31-33 that provided evidence on the benefits of early
initiation of ART.
The HPTN 052 trial randomly assigned participants to
initiation of ART at CD4 cell counts of 350/mL3 to 550/mL3
or delayed initiation at CD4 cell counts of 250/mL3 or less.27
At a mean follow-up of 2.1 years, initiation of ART at higher CD4
counts was associated with decreased risk of AIDS-related events
(4.5% vs 7.0%; relative risk [RR], 0.65 [95% CI, 0.44-0.95]).
Effects on other outcomes (including all-cause mortality; AIDS-
related mortality; and a composite outcome including death, seri-
ous AIDS-related events, and serious non–AIDS-related events,
such as bacterial infection or cancer) favored early initiation of
ART but were not statistically significant.28 The START trial found
decreased risk of a composite end point of all-cause mortality,
serious AIDS-related events, and serious non–AIDS-related
events,29 and the TEMPRANO ANRS trial found decreased risk of
a composite end point of all-cause mortality, progression to AIDS,
AIDS-defining cancer, and non–AIDS-defining invasive bacterial
disease30 in participants treated with immediate ART at CD4 cell
counts greater than 500/mL3, compared with delayed treatment
at lower CD4 counts.
The 3 cohort studies31-33 also provide evidence of benefit to
early initiation of ART. Seven-year follow-up from the HIV Cohorts
Analyzed Using Structural Approaches to Longitudinal
(HIV CAUSAL) Collaboration showed that ART initiation at CD4
cell counts greater than 500/mL3 was associated with decreased
risk of all-cause mortality and a composite end point of progres-
sion to AIDS or death compared with initiation at CD4 cell counts
less than 350/mL3.31 A second cohort study from Canada found
that initiation of ART at CD4 cell counts greater than 500/mL3
was associated with lower probability of mortality and AIDS-
related morbidity than initiation at CD4 cell counts less than
500/mL3 or less than 350/mL3.32 Last, a US-based cohort study
found that compared with initiation of ART within 6 months of
CD4 cell counts decreasing to less than 500/mL3, there were
greater risks of 10-year all-cause mortality associated with ART
initiation within 6 months of CD4 cell counts decreasing to less
than 350/mL3 (RR, 1.08 [95% CI, 1.00-1.16]) or 200/mL3 (RR, 1.25
[95% CI, 1.08-1.44]).33
Early initiation of ART and viral suppression has also been
shown to decrease risk of HIV transmission.27 Longer-term
follow-up from the HPTN 052 trial showed that early ART initiation
is associated with a reduction in risk of HIV transmission to
uninfected partners (RR for virologically linked transmission, 0.07
[95% CI, 0.02-0.22]),34 and 3 observational studies (Partners of
People on ART—A New Evaluation of the Risks [PARTNER],35
PARTNER2,36and Opposites Attract37) found no cases of HIV trans-
mission among serodiscordant couples when the partner living
with HIV was treated with ART and had viral suppression, during
1238, 1593, and 232.2 couple-years of follow-up, respectively.
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In its discussions about the age range for routine screening, the
USPSTF considered the evidence on the age-stratified incidence of
HIV infection and data on the prevalence of sexual activity in youth.
Data from the CDC 2017 HIV Surveillance Report show a significant
increase in HIV diagnoses in the United States starting at age 15
years (compared with ages 13-14 years).2 In addition, 52% of youth
in grades 9 through 12 reported engaging in sexual contact in the
most recent Youth Risk Behavior Surveillance survey,38 and in ear-
lier survey data, approximately one-third of youth reported engag-
ing in sexual intercourse before age 16 years.39 CDC surveillance
data also show a significant decrease in HIV diagnoses among
adults 65 years and older.2
The USPSTF found no studies that compared rates of mother-
to-child transmission of HIV infection between pregnant women
screened and not screened for HIV infection. The USPSTF found
several cohort studies and RCTs that provided evidence on the
effectiveness of ART in decreasing rates of mother-to child trans-
mission of HIV infection in pregnant women living with HIV.24,25
The cohort studies, all conducted in North America, Europe, or
Israel, reported rates of mother-to-child transmission of less than
1.0% to 2.8% among women treated with 3 antiretroviral drugs,
compared with 9.1% to as much as 67% in 1 small cohort study
among untreated women.24,25 The RCTs were conducted in Africa
or India (ie, settings with a lower United Nations Human Develop-
ment Index than the United States) and compared the effects of
a heterogeneous group of prenatal, peripartum, and postpartum
ART interventions of varying durations on rates of mother-to-child
transmission of HIV infection. Across all studies (both the cohort
studies and RCTs), later initiation of ART during pregnancy or treat-
ment with fewer than 3 antiretroviral drugs was associated with
greater risk of mother-to-child transmission of HIV infection.24,25
Potential Harms of Screening and Treatment
Longer-term use of individual antiretroviral drugs and different
ART regimens may be associated with several harms. The USPSTF
reviewed several studies that reported on the long-term cardio-
vascular, neuropsychiatric, hepatic, renal, or bone (fracture)
harms associated with the use of various antiretroviral drugs and
ART regimens.22,23
Two good-quality RCTs (duration, 2.8-5 years) found no differ-
ences in riskof serious cardiovascular or cerebrovascular eventsbe-
tween different ART regimens.40,41 Findings on the cardiovascular
harms of the drug abacavir are mixed. A meta-analysis of 26 trials
found no association between abacavir use and risk of myocardial
infarction,42 but 2 cohort studies found that abacavir was associ-
ated with increased risk (RR, 1.98 [95% CI, 1.72-2.29] and odds ra-
tio, 1.50 [95% CI, 1.26-1.79]).43,44
The drug efavirenz has been linked to neuropsychiatric
adverse events, including depression and suicidal ideation.45 A sys-
tematic review (n = 8466; mean duration, 78 weeks) reported
rates of neuropsychiatric adverse events among participants taking
efavirenz; 29.6% (95%CI, 21.9%-37.3%) experienced events of any
grade, 6.1% (95% CI, 4.3%-7.9%) experienced severe neuropsychi-
atric adverse events, 3.3% (95% CI, 2.2%-4.3%) had depression,
and 0.6% (95%CI, 0.2%-1.1%) had suicidal ideation.46 However, an
analysis of the Data Collection on Adverse Events of Anti-HIV Drugs
(D:A:D) study, a large (n >49000) international study of 11 pro-
spective cohorts from Europe, Australia, and the United States,
found no association between use of efavirenz and death from
suicide,47 and an analysis of a large (n = 19 983) US administrative
cohort found no association between initiation of efavirenz and
increased risk of suicidal ideation.48
An analysis of the D:A:D cohorts found that tenofovir diso-
proxil fumarate (relative rate, 1.46 [95% CI, 1.11-1.93]) and fosam-
prenavir (relative rate, 1.47 [95% CI, 1.01-2.15]) were associated
with increased risk of end-stage liver disease or hepatocellular
carcinoma, independent of viral hepatitis status, and that emtri-
citabine was associated with decreased risk of these outcomes
(relative rate, 0.51 [95% CI, 0.32-0.83]).49 However, the absolute
risk of ART-related liver deaths in the D:A:D cohorts was low
(0.04 deaths per 1000 person-years).50 Another D:A:D analysis
found an association between use of tenofovir disoproxil fuma-
rate (rate ratio, 1.14 cases per year of exposure [95% CI, 1.10-1.19])
or ritonavir-boosted atazanavir (rate ratio, 1.20 cases per year of
exposure [95% CI, 1.13 to 1.26]) and increased risk of chronic kid-
ney disease.51 A second observational study also found that teno-
fovir disoproxil fumarate was associated with an increased risk of
renal adverse events,52 and a third observational study found that
tenofovir disoproxil fumarate was associated with kidney dys-
function, which was relatively mild and tended to be stable over
several years.53
A cohort study found that ever use of tenofovir disoproxil fu-
maratewasassociatedwith increasedriskof fracturecomparedwith
nonuse (adjusted incidence rate ratio, 1.40 [95% CI, 1.05-1.70]) af-
ter follow-up of more than 86000 person-years. However, there
was no difference in risk of fracture based on cumulative duration
of use (adjusted incidence rate ratio per 5 years of exposure, 1.08
[95% CI, 0.94-1.25]).54
The USPSTF reviewed several studies that assessed the
harms of ART during pregnancy.24,25 One fair-quality RCT and 7
cohort studies found that antenatal ART was associated with
increased risk of preterm birth (before 37 weeks of gestation)
compared with no treatment or zidovudine monotherapy.55-62
No clear associations were found between ART and overall birth
defects, low birth weight, small size for gestational age, stillbirth,
or neonatal death.24,25 There were mixed findings on cardiovas-
cular congenital anomalies.24,25 Two studies of HIV-exposed,
uninfected infants and children found that in utero exposure to
ART was not associated with lower scores on Wechsler intelli-
gence and achievement tests in children aged 7 to 13 years63 and
may be associated with less neurodevelopmental impairment64
compared with no in utero exposure to ART.
Evidence on maternal harms associated with ART during
pregnancy is limited. Three older studies suggest that ART (espe-
cially with a protease inhibitor) may be associated with an
increased risk of gestational diabetes.65-67 One RCT found no dif-
ference in risk of anemia between combination ART (zidovudine,
lamivudine, and ritonavir-boosted lopinavir) starting at 28 to 36
weeks of gestation vs zidovudine monotherapy starting at 34 to
36 weeks of gestation until onset of labor, followed by zidovudine
and a single dose of nevirapine at the onset of labor.68 Another
RCT found that treatment with zidovudine-based ART resulted in
increased risk of maternal adverse events vs zidovudine mono-
therapy (21% vs 17%; P = .008) and increased risk of abnormali-
ties in blood chemistry values (5.8% vs 1.3%; P < .001), primarily
elevated alanine aminotransferase levels.55
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Estimate ofMagnitude of Net Benefit
TheUSPSTF concludeswith high certainty that early detection and
treatment of HIV infection would result in substantial benefits.
Screening for HIV infection in all adolescents and adults aged 15 to
65 years, persons at increased risk of infection, and pregnant per-
sons would allow for earlier and expanded detection of HIV infec-
tion, thus resulting in earlier medical and behavioral interventions
and treatment.
The USPSTF found convincing evidence that early initiation of
ART for HIV infection, regardless of CD4 cell count, improves clini-
cal outcomes and reduces the risk of sexual transmission. The
USPSTF found adequate evidence that the harms of early detec-
tion and treatment of HIV infection are small, and the clinical ben-
efits of ART substantially outweigh the potential risks of treatment
in persons living with HIV. The USPSTF also found convincing evi-
dence that screening for HIV infection in pregnant women confers
substantial clinical benefits for both themother and infant,with ad-
equate evidence that the potential harms are small.
On thebasis of these findings, theUSPSTFconcludeswithhigh
certainty that early detection and treatment of HIV infection re-
sults in substantial net benefit.
HowDoes Evidence FitWith Biological Understanding?
Diagnosis and initiation of treatment of HIV infection at the earliest
stagepossible isassociatedwith improvedhealthoutcomes.Screen-
ingwithhighlyaccuratetestsallowsfordiagnosis in therelatively long
preclinicalphaseofHIV infection.Early treatmentwithARThasbeen
showntoeffectivelysuppressviral loadanddecreasetheriskofAIDS-
related events, serious non–AIDS-related events, and death in per-
sons livingwithHIV infection.Effective treatmentalsodecreases risk
ofsexual transmissionofHIVbysuppressingviral load in infectedper-
sons. Diagnosis and effective treatment in pregnant persons living
withHIVdecreases the risk ofmother-to-child transmission by sup-
pressingviral loadandallowing for implementationofotherpreven-
tion strategies (ie, appropriate antiretroviral treatment of the new-
born and counseling about avoidance of breastfeeding).
Response to Public Comment
A draft version of this recommendation was posted for public
comment on the USPSTF website from November 20 through
December 26, 2018. In response to public comment, the USPSTF
added information and clarified language regarding assessment of
risk, high-prevalence HIV settings, and persons who may be at in-
creased risk and warrant rescreening, as well as the importance of
linkage tocareafter anHIVdiagnosis. TheUSPSTFalso clarified that
personsnotat increased riskmaynotneedrescreening.TheUSPSTF
clarified language describing the epidemiology of HIV and pro-
vided additional details on the HPTN 052 study. The USPSTF also
added information about the data it considered in its discussions
about the age at which to start and end routine screening.
Update of Previous USPSTF Recommendation
In 2013, the USPSTF recommended screening for HIV infection in
adolescents and adults aged 15 to 65 years, screening in younger
adolescents and older adults at increased risk, and screening in all
pregnant women.69 The current updated recommendation con-
tinues to strongly recommend screening for HIV infection in ado-
lescents and adults aged 15 to 65 years, younger adolescents and
older adults at increased risk, and all pregnant persons.
Recommendations of Others
In 2006, the CDC recommended routine voluntary screening
for HIV infection in all adolescents and adults aged 13 to 64
years, regardless of other recognized risk factors, unless HIV
prevalence was documented to be less than 0.1% within a patient
community.10 The CDC recommends that all persons should
be screened at least once in their lifetime and those with risk fac-
tors be screened more frequently (eg, annually); the CDC also
recently recommended that clinicians consider testing sexually
active men who have sex with men more frequently (eg, every 3
to 6 months) based on risk behaviors, community HIV prevalence,
and other considerations.11
In 2009, the American College of Physicians recommended
routine screening for HIV infection.70 The Infectious Diseases Soci-
ety of America recommends routine screening for HIV infection in
all sexually active adults and pregnant women.71 In 2017, ACOG
reaffirmed a previous recommendation that all females aged 13 to
64 years be tested at least once in their lifetime and annually there-
after if they are assessed to have risk factors for HIV infection.72
The American Academy of Pediatrics recommends universal
screening for HIV infection once between the ages of 15 and 18
years, and annual reassessment and testing of persons at increased
risk.73 The American Academy of Family Physicians supports the
2013 USPSTF recommendations, except it recommends that rou-
tine screening begin at age 18 years and that only adolescents at
increased risk be tested at younger ages.74
The CDC,10 ACOG,12 American Academy of Pediatrics,75,76
American College of Physicians,70 and American Academy of Fam-
ily Physicians74 recommend routine screening for HIV infection in
all pregnant women using an opt-out approach, and rapid screen-
ing for womenwho present in labor whose HIV status is unknown.
The CDC10 and ACOG12 recommend repeat testing during the third
trimester inwomenwith risk factors and inwomen living or receiv-
ingcare inhigh-incidencesettingswhohadanegative test resultear-
lier inpregnancy; theCDC10notes that repeat testing in the third tri-
mestermaybe considered for allwomenwith a negative test result
early in pregnancy.
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